The Efficacy and Safety of Seladelpar for Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.
Publication/Presentation Date
9-1-2025
Abstract
BACKGROUND AND OBJECTIVE: Seladelpar is an oral, once-daily medication that improves cholestasis through its selective peroxisome proliferator-activated receptor (PPAR-δ) agonism. It shows promising efficacy in treating primary biliary cholangitis (PBC) patients.
METHODS: A systematic review and meta-analysis synthesizing evidence from randomized controlled trials (RCTs) obtained from PubMed, Cochrane, Scopus, and WOS until July 19th, 2025. Dichotomous outcomes were reported using risk ratio (RR) and continuous outcomes using mean difference (MD), with a 95% confidence interval (CI).
RESULTS: Three RCTs with 499 patients were included. Seladelpar was significantly associated with an increased ALP normalization (RR: 21.12 with 95% CI [4.14, 107.58],
CONCLUSION: Seladelpar improved liver biomarkers of cholestasis and reduced pruritus in patients with PBC without significantly increasing the adverse effects. This makes seladelpar a promising addition to the treatments available for PBC.
Volume
9
Issue
9
First Page
70265
Last Page
70265
ISSN
2397-9070
Published In/Presented At
Abuelazm, M., Alsakarneh, S., Tanashat, M., Manasrah, A., Ibrahim, A. A., Parajuli, S., Eltaly, H., & Amin, A. M. (2025). The Efficacy and Safety of Seladelpar for Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. JGH open : an open access journal of gastroenterology and hepatology, 9(9), e70265. https://doi.org/10.1002/jgh3.70265
Disciplines
Medicine and Health Sciences
PubMedID
40893425
Department(s)
Fellows and Residents
Document Type
Article